Breast Cancer Clinical Trials in Torrance, California

6 studies are recruiting for breast cancer in Torrance, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

   The EXActDNA-003 study will prospectively enroll participants who are planning to undergo chemotherapy for high-risk, early breast cancer, who are willing to provide tissue and blood specimens for circulating tumor DNA (ctDNA) analysis. Participants will be followed for up to 5.5 years.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Harbor-UCLA Medical Center - Hematology / Oncology, Torrance, California

   Locations

   61 in total

   Run by

   Exact Sciences Corporation

   See if you can join NCT06401421 on ClinicalTrials.gov

2. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

   The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California

   Locations

   433 in total

   Run by

   Pfizer

   See if you can join NCT07062965 on ClinicalTrials.gov

3. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

   The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Torrance Memorial Physician Network- Cancer Care, Torrance, California

   Locations

   567 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT06492616 on ClinicalTrials.gov

4. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Torrance Memorial Physician Network - Cancer Care, Torrance, California

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

5. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

   This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Torrance Memorial Cancer Center, Torrance, California

   Locations

   79 in total

   Run by

   BriaCell Therapeutics Corporation

   See if you can join NCT06072612 on ClinicalTrials.gov

6. Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms

   Both Tart Cherry and Omega 3 FAs have better side effect profiles compared to other commonly used medications for AIMSS, such as nonsteroidal anti-inflammatories, steroids, and serotonin norepinephrine reuptake inhibitors. Additionally, in our clinics we often find that patients tend to be more rec…

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   CS Cancer at the Hunt Cancer Center, Torrance, California

   Locations

   2 in total

   Run by

   Philip Chang

   See if you can join NCT06123286 on ClinicalTrials.gov